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R573together the sister DNAs of each
chromosome from S phase until
mitosis. This paper underscores how
poorly we actually understand the
interconnections between DNA
replication and the establishment of
cohesion.
But irrespective of the mechanism,
this paper suggests that both
nucleoside supplementation and
Wapl inactivation might be valid
approaches to correct the CIN
phenotype of pRB-deficient tumours.
Nucleoside supplementation may
carry significant risk, as elevated
dNTP levels can lead to increased
cellular mutation rates [18]. Targeting
Wapl for anti-cancer therapy may also
not be without risk, as Wapl
inactivation in healthy cells causes
segregation defects by itself. However,
Wapl depletion causes a
p53-dependent cell-cycle arrest in
non-cancerous cells, which should
protect healthy cells against the
adverse consequences of Wapl
inactivation. Wapl loss in healthy cells
leads to unwanted cohesin on
chromosome arms in mitosis, whereas
its inactivation in pRB-deficient
cells appears to restore cohesion
levels to a basal state that is
optimal for proper chromosome
segregation [9,19,20].
Wapl has no known enzymatic
activity, so it will not be straightforward
to target Wapl with a drug. Also,
how Wapl antagonises cohesin
complexes is largely a mystery. It
will therefore be important to further
elucidate the cellular pathways by
which Wapl regulates cohesion in
order to uncover other players in this
pathway that may be better drug
targets. Such a drug could be highly
beneficial as adjuvant therapy to
prevent the resistance of CIN tumours
to a primary drug that specifically
targets the cancer cells.
We have learned a lot about
chromosomal instability since
Hansemann’s pioneering work of the
1890s. This new paper [9] now provides
us with important new insight into the
cause of CIN, and at the same time
pinpoints potential therapeutic targets
for counteracting CIN. Important
discoveries often open up many
possibilities for future studies, and
this paper is clearly no exception.
Both fundamental scientists and
translational researchers now have
plenty of newquestions that arewaiting
to be answered.References
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and Products.Recent reports have identified committed innate lymphoid cell (ILC) precursors
and tissue-resident ILC subsets that have unique functional attributes. Taken
together, these studies provide a framework for understanding how distinct
ILCs are generated during hematopoiesis and further suggest additional
parallels between models of ILC and T helper cell differentiation.Nicolas Serafini1,2, Wei Xu1,2,
and James P. Di Santo1,2,*
The discovery of novel T helper cell
subsets — Th17, Th9, Th22, regulatory
and follicular helper T cells — thatextended Mosmann’s Th1/Th2
paradigm was accompanied by an
explosion of research into the
mechanisms that control T helper cell
differentiation. In a similar way, the
recent description of distinct innate
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Figure 1. Novel ILC precursors suggest a new model of ILC development.
Hematopoietic stem cell-derived CLP (common lymphoid progenitor) cells have the potential
to generate adaptive (T and B cell) and innate lymphoid cells (ILC). ILC development requires
Id2 expression for conventional Eomes+ NK cells (cNK) as well as for ‘helper’ ILCs that appear
to derive from a common helper ILC precursor (ChILP). Lymphoid-tissue inducer (LTi) cells
appear to branch off from ChILP prior to PLZF acquisition in ChILP. PLZF+ ChILP can generate
ILC1 (including ‘tissue-resident’ NK cells) as well as diverse ILC2 and ILC3 subsets.
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R574lymphoid cell (ILC) subsets that
specialize in rapid cytokine secretion
has sparked an active interest in trying
to decipher the molecular pathways
that orchestrate ILC differentiation.
Two recent reports [1,2] now provide
important clues to how ILC
diversification is achieved by
identifying ILC precursors in fetal and
adult life and by characterizing peculiar
‘tissue-resident’ ILCs.
ILCs comprise a relatively poorly
characterized branch of the
lympho-hematopoietic tree. These
cells are composed of several distinct
groups of rapidly responding effector
cells that have important roles in
defense at barrier surfaces, as well as
roles in tissue homeostasis and repair
after infection or inflammation [3].
Group 1 ILCs (or ILC1 cells) consist of
natural killer (NK) cells and other innate
cells that express the transcription
factor T-bet and produce interferon-g
(IFN-g): ILC1 cells have been shown to
play a major role in the defense againstviruses, intracellular bacteria and
protozoa. Group 2 ILCs (or ILC2 cells)
express the transcription factors
GATA-3 and RORa and secrete the
cytokines interleukin-5 (IL-5) and IL-13.
ILC2 cells are important in the immune
response against helminthes and
influenza infection and are associated
with allergic airway inflammation.
Group 3 ILCs (or ILC3 cells) are a
heterogeneous family of cells that
express the orphan nuclear receptor
RORgt and produce IL-17A and/or
IL-22. ILC3 cells are enriched at
mucosal sites and appear to regulate
barrier function and epithelial cell
homeostasis. The striking functional
parallels between ILC groups and T
helper cell subsets has led to the notion
that ILCs represent innate versions of T
helper cells, thereby allowing for the
generation of a coordinated cytokine
‘milieu’ during the early (innate) and late
(adaptive) phases of an immune
response against pathogens. Since
their identification, a major unsolvedquestion has been — how are these
diverse ILCs generated during
hematopoiesis?
During lymphocyte development,
pluripotent hematopoietic stem cells
successively shed erythroid and
myeloid potentials to give rise to
common lymphoid progenitors (CLPs)
that can generate B and T cells of the
adaptive immune system as well as all
known ILC subsets. Previous studies
had identifiedmore restricted lymphoid
precursors that, like CLPs, do not
express mature lymphocyte cell
surface markers but do express
receptors for stem cell factor and IL-7.
Within this population, a subset that
expresses the integrins a4b7 has lost B
and T cell potential, but retains the
capacity to generate NK cells and
lymphoid tissue-inducer (LTi) cells
[4–6]. Based on this knowledge, it was a
good bet that this population would
contain the elusive ILC precursor. The
problem: how to identify it?
In one of the two new studies,
Andreas Diefenbach’s group [1] made
use of the fact that all known ILC
subsets require expression of Id2
(inhibitor of DNA binding 2), a
transcription factor that regulates E
protein activity (reviewed in [7]). Using
Id2 reporter mice [8], this group found
and characterized a rare Id2+a4b7+Lin2
IL-7Ra+ population in the bone marrow
of normal mice that, after adoptive
transfer to mice, was able to generate
an unusual CD49a+ NK ILC1 subset
(more below), ILC2 cells and ILC3 cells
(including both LTi and NKp46+
subsets), but not myeloid, B, T or NK
cells [1]. This precursor population was
denoted ChILP (for common helper ILC
precursor) and could generate multiple
ILC subsets in vitro after extended
culture of single ChILP on OP9 stromal
cells expressing the Notch1 delta-like
ligand 1. Thus, this ChILP population
fulfills the criteria for committed ILC
precursors (Figure 1).
Albert Bendelac’s group has a
long-standing interest in another innate
lymphocyte subset, the NK-T cell.
This group demonstrated that the
transcription factor Zbtb16 (also known
as promyelocytic leukaemia zinc finger,
PLZF) was a critical factor in NK-T cell
differentiation [9] and recently created
PLZF fate-mapping reporter
(PLZFCreGFP) mice that can identify
cells that have expressed PLZF in their
past history [2]. While characterizing
PLZFCreGFPmice, this group found that,
although NK-T cells expressed GFP
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R575and were ‘fate-mapped’, a large
fraction of GFP2 ILCs was
fate-mapped as well. This unexpected
result suggested that transient PLZF
expression was a characteristic of ILC
development. The authors then
examined a4b7+Lin2IL-7Ra+
progenitor cells and were able to
identify a subset that expressed PLZF
(i.e. were GFP+) and after in vivo
transfer could give rise to the same
peculiar NK ILC1 liver subset, lung
NK1.1+ cells, systemic ILC2 cells and
mucosal CD42 ILC3 cells, but not to B
or T cells. In vitro, fetal liver or adult
bone marrow PLZF+a4b7+Lin2IL-7Ra+
cells could rapidly generate ILC1, ILC2
and ILC3 subsets (but not LTi cells)
when cultured on OP9 stromal cells.
A fraction of fetal liver PLZF+a4b7+Lin2
IL-7Ra+ cells could generate all ILC
groups at the single-cell level [2].
Thus, the PLZF+a4b7+Lin2IL-7Ra+
phenotype identifies a committed ILC
precursor in both fetal and adult
life (Figure 1).
Are the committed ILC precursors
identified by Bendelac’s and
Diefenbach’s groups the same cells
or related cells? The fact that both
subsets generate multiple, distinct
ILCs in vivo and in vitro, lack B and
T cells and have reduced NK cell
potential strongly suggests that they
are largely overlapping populations.
Along these lines, a substantial fraction
of ChILP express PLZF [1], and PLZF+
ILC precursors express high levels of
Id2 transcripts [2]. Moreover, PLZF+
cells can be induced from PLZF–a4b7+
Lin2IL-7Ra+ cells by activation of
Notch. So it is possible that the PLZF+
ILC precursor is represented as a
subset of a larger ChILP population.
Still, the definitive answer to this
question awaits experiments using
mice bearing both Id2 and PLZF
reporters.
There are several intriguing
differences between the phenotype
and function of ChILP and PLZF+ ILC
precursors that will require further
study. The most notable difference is
that ChILP generate a broader range
of ILC3 cells (including CD4+ LTi
cells) compared with PLZF+ ILC
precursors. Bendelac’s group
carefully studied transcription factor
protein expression in fetal and adult
a4b7+Lin2IL-7Ra+ cells and found
considerable heterogeneity: PLZF+
ILC precursors co-expressed GATA-3
and TOX proteins, but PLZF2 cells
also were present that includedCXCR6+ RORgt+ cells that appear to be
related to the ILC3 subset [2,10]. In
contrast, the ChILP population
expressed PLZF (but not GATA-3) and
was apparently devoid of Rorc-
expressing cells [1]. The different
approaches used in the two
studies — intracellular protein staining
versus fluorescent reporters — may
explain these inconsistencies, but it
could indicate that the ChILP
population harbors several distinct
precursors with differing ILC
potentials.
Another intriguing question is
why these committed ILC precursor
populations have little, if any, in vivo
NK cell potential? The simple answer
may be that NK cells are not ‘true’
ILCs and that their committed
precursors and developmental
pathways are unique and different
from other ILCs. Still, NK cells
critically rely on Id2 [11,12], are
derived from IL-7Ra+ CLPs in vivo
[13], and some NK cells are
fate-mapped in PLZFCreGFP mice [2],
suggesting a link with these newly
described ILC precursors. Another
difficulty in addressing NK cell fate is
that NK cells are not a single lineage,
but include several developmentally
distinct subsets that have different
phenotypic markers, functional
attributes and tissue localizations
[14,15]. Several transcription factors
drive the development of NK cell
diversity, including Nfil3, GATA-3,
Tbx21, and Eomes (reviewed in [16]).
Recently several studies from
Yokoyama’s and Walzer’s groups
demonstrated that a subset of liver
CD49a+ NK cells (lacking the DX5
marker and expressing TRAIL [17])
could develop independently of
Eomes and Nfil3, thus distinguishing
‘conventional’ Eomes+ NK cells from
‘tissue-resident’ Eomes2 NK cells
that produce higher levels of
cytokines, especially tumor necrosis
factor a [18,19]. Moreover,
Diefenbach’s group additionally
identified in mucosal sites Eomes2 NK
ILC1 cells that were GATA-3- and
Tbx21-dependent and expressed
many common markers with ‘tissue-
resident’ NK cells [1]. Thus, at least
three distinct lineages of NK1.1+
NKp46+ ILC1 and NK cells can be
discerned and the relationship
between these populations remains
unclear. Interestingly, the committed
ILC precursors from Bendelac and
Diefenbach’s group robustlygenerated CD49a+Eomes2 hepatic NK
cells (and the mucosal equivalents)
after in vivo transfer. In contrast, the
contribution of ChILP or PLZF+
precursors to conventional NK cell
homeostasis was less evident,
although more detailed analyses need
to be performed, e.g. examination of
Eomes and CD49a expression.
These observations leave open the
possibility that additional NK
cell-restricted ILC precursors exist
that may express levels of Id2 or PLZF
that are not revealed by the reporter
mice used in these studies.
These recent reports add
substantially to our understanding of
the developmental pathways that
generate diverse ILC subsets from
lympho-hematopoietic precursors.
The isolation of ILC precursors should
facilitate the identification of the
molecular signatures that are
associated with ILC commitment
and may provide new clues to
understand the process of ILC subset
specification that clearly generates
phenotypic and functional diversity
between and within different ILC
groups. As ILC diversification may
be considered an evolutionary
predecessor to adaptive T helper cell
differentiation, these molecular clues
could provide new ways to consider
the driving forces behind adaptive
immune responses.References
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